Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-MUC17/CD3 BiTE antibody AMG 199

A half-life extended (HLE), human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human mucin 17 (MUC17), and one directed against human CD3, a T-cell surface antigen found on T lymphocytes, with potential antineoplastic activity. Upon administration, anti-MUC17/CD3 BiTE antibody AMG 199 binds to both CD3 on T cells and MUC17 expressed on tumor cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against MUC17-expressing tumor cells. MUC17, a member of the mucin family of glycoproteins, is overexpressed in a variety of tumor cells of epithelial origin and plays a key role in tumor cell dissemination.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-MUC17 x anti-CD3 BiTE AMG 199
anti-MUC17/CD3 bispecific antibody AMG 199
bispecific T-cell engager antibody AMG 199
BiTE antibody AMG 199
MUC17/CD3-directed bispecific T-cell engager antibody AMG 199
MUC17xCD3 bispecific T-cell engager AMG 199
Code name:AMG 199
AMG-199
AMG199
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search